NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against UnitedHealth Group Incorporated (“UnitedHealth” or the “Company”) (NYSE: UNH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether UnitedHealth and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. You have until July 7, 2025, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired UnitedHealth securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com. [Click here for information about joining the class action] On April 17, 2025, UnitedHealth issued a press release reporting its financial results for the first quarter of 2025 and issuing revised full year guidance. In the press release, UnitedHealth revised its 2025 net earnings outlook to a range of $24.65 to $25.15 per share (compared to previous guidance of $28.15 to $28.65 per share) and revised its 2025 adjusted earnings outlook to a range of $26.00 to $26.50 per share (compared to previous guidance of $29.50 to $30.00 per share). UnitedHealth’s press release also indicated that the Company was allowing increased coverage and care for Medicare Advantage beneficiaries, advising that its revised outlook reflected, among other things, “[h]eightened care activity indications . . . which became visible as the quarter closed, far above the planned 2025 increase[.]” On this news, UnitedHealth’s stock price fell $159.71 per share, or 27%, over the following two trading sessions, to close at $425.33 per share on April 18, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] ext. 7980
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UnitedHealth Group Incorporated of Class Action Lawsuit and Upcoming Deadlines – UNH
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...